Page 415


measurement, 201
patient perspectives, 188
relapses, 32
Social Security Administration disability criteria, 401, 402
treatment, 138-140
as side effect, 125, 135, 139
Atrophy, 35, 38, 39, 122, 278, 356
Attention, 118, 154, 200, 403
Autoantigens, 6, 66, 67, 71-74 (passim), 91, 93, 100, 251-255, 257, 279, 280, 354, 355, 357, 398
Autogenous vaccine, 409
Autoimmunity, see
Immune response
Autologous Blood and Marrow Transplant Registry of North America, 313, 314-315
Autopsies
asymptomatic MS, 30
axonal damage and demyelination, 64
brain banks, 316-318, 332, 339
tissue banks, other, 365
Avonex, see
Beta-interferon
Axons, 3, 7, 20
see also

Demyelination;
Myelin;
Remyelination;
Synapses
animal models, 95
atrophy, 35, 38, 39
autopsies, 64
degeneration, 58-59, 64, 92, 241-243, 244, 251, 266-267, 278, 280-281, 283, 291, 349, 350, 356
cognitive impairment, 118
electrical impulse conduction, 20, 56, 57, 58, 65, 242, 247, 255, 349, 350
inflammation, 242, 280-281
N-acetyl aspartate, 38, 39-40, 64
magnetic resonance imaging, 35, 38, 39-41, 241
pain, 163
physiology, 54-65, 246;
see also

“electrical...” supra
plasticity, 58, 65, 245, 246-247, 249-251, 291, 349
research recommendations, 65-70, 241-243, 244, 246-247, 249-251, 255, 266-267, 278, 349, 350
secondary progressive MS, 30
T1-weighted hypointense lesions, density measurements, 40
treatment, 243, 278, 280-281, 283, 288, 289, 291, 358
weakness, 136
Azathioprine, 390

B


B cells, 6, 395
animal models, 91
autoreactive/demyelinating, 6, 60, 68, 70, 71, 74, 93, 251, 253, 255, 355
cerebrospinal fluid (CSF), 42, 74, 265-266
cloning, 42, 93
biomarkers, 265-266
experimental autoimmune encephalomyelitis (EAE), 93
B lymphocytes, see
B cells
Back pain, 145, 160, 165
Baclofen, 132-133, 165, 289
Bacteria, 15, 67, 78, 283, 366
Barthel Index, 198, 200, 205, 215
Beck Depression Inventory, 121, 122
Bee venom, 408
Behavioral factors
see also

Functional status;
Patient perspectives
patient adherence to therapy, 51-52
measurement, 197
modification therapy, 123, 153
Social Security Administration disability criteria, 403
Bentyl, 144-145
Benzodiazapines, 133, 165
Beta-interferon, 35, 48-51, 60, 277, 284, 298, 307, 361, 392
animal studies, 92
Avonex/Rebif, 49, 50, 388, 396
Betaseron, 49, 51, 53, 388
cognitive impairment, 119
depression, 52, 123, 126-127
neutralizing antibodies, 51, 52, 97
side effects of, 49, 52, 123, 126-127, 388
Biological markers, 42, 44-45, 262-267, 308, 366-367
B cells, 265-266
cerebrospinal fluid (CSF), 30, 41-42
clinical studies, 261, 262
cytokine production, 259, 263-264
demyelination, 44, 45
disease subtypes, 261, 262-267


The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement